BSE Live
Nov 13, 16:01Prev. Close
1188.15
Open Price
1190.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 13, 15:59Prev. Close
1183.60
Open Price
1191.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1210.20 (701)
| Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 | |
| Total Share Capital | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 | |
| Reserves and Surplus | 32,595.24 | 29,784.21 | 26,781.26 | 24,517.39 | 21,871.28 | |
| Total Reserves and Surplus | 32,595.24 | 29,784.21 | 26,781.26 | 24,517.39 | 21,871.28 | |
| Total Shareholders Funds | 32,653.32 | 29,842.80 | 26,839.85 | 24,575.98 | 21,929.87 | |
| Minority Interest | -6.39 | 8.00 | 12.00 | -1.93 | -0.88 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 1,561.65 | 2,134.90 | 618.96 | 249.21 | 168.40 | |
| Deferred Tax Liabilities [Net] | 303.27 | 356.56 | 389.61 | 410.96 | 574.56 | |
| Other Long Term Liabilities | 307.85 | 304.42 | 363.07 | 359.73 | 359.78 | |
| Long Term Provisions | 282.93 | 225.70 | 172.72 | 171.79 | 157.11 | |
| Total Non-Current Liabilities | 2,455.70 | 3,021.58 | 1,544.36 | 1,191.69 | 1,259.85 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 6,380.03 | 4,180.32 | 4,242.56 | 2,123.56 | 4,802.71 | |
| Trade Payables | 4,188.85 | 4,454.16 | 3,871.31 | 2,703.05 | 2,794.68 | |
| Other Current Liabilities | 3,837.90 | 3,307.86 | 3,179.38 | 3,158.81 | 2,895.83 | |
| Short Term Provisions | 275.56 | 256.79 | 200.53 | 170.56 | 171.93 | |
| Total Current Liabilities | 14,682.34 | 12,199.13 | 11,493.78 | 8,155.98 | 10,665.15 | |
| Total Capital And Liabilities | 49,784.97 | 45,071.51 | 39,889.99 | 33,921.72 | 33,853.99 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 12,189.43 | 11,545.51 | 7,995.38 | 7,728.44 | 6,886.62 | |
| Intangible Assets | 1,986.74 | 2,352.13 | 2,432.24 | 2,328.23 | 2,058.06 | |
| Capital Work-In-Progress | 3,266.00 | 2,739.39 | 4,496.40 | 2,937.56 | 2,428.89 | |
| Fixed Assets | 19,076.13 | 17,766.36 | 15,817.63 | 13,803.87 | 12,006.21 | |
| Non-Current Investments | 251.70 | 94.78 | 391.74 | 618.30 | 431.22 | |
| Deferred Tax Assets [Net] | 1,292.96 | 1,212.64 | 677.49 | 288.59 | 452.68 | |
| Long Term Loans And Advances | 6.74 | 226.87 | 5.57 | 6.32 | 7.26 | |
| Other Non-Current Assets | 1,376.96 | 970.08 | 855.82 | 606.53 | 704.21 | |
| Total Non-Current Assets | 22,622.51 | 20,865.88 | 18,344.32 | 15,799.03 | 14,030.48 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.01 | 50.58 | 151.00 | 378.85 | 159.79 | |
| Inventories | 10,543.72 | 9,808.23 | 8,511.23 | 7,553.85 | 9,026.57 | |
| Trade Receivables | 5,745.93 | 4,816.74 | 4,466.38 | 4,012.26 | 3,503.28 | |
| Cash And Cash Equivalents | 8,235.49 | 6,278.30 | 6,084.20 | 4,190.01 | 5,474.28 | |
| Short Term Loans And Advances | 15.56 | 12.86 | 12.43 | 12.71 | 14.32 | |
| OtherCurrentAssets | 2,621.75 | 3,238.92 | 2,320.43 | 1,975.01 | 1,645.27 | |
| Total Current Assets | 27,162.46 | 24,205.63 | 21,545.67 | 18,122.69 | 19,823.51 | |
| Total Assets | 49,784.97 | 45,071.51 | 39,889.99 | 33,921.72 | 33,853.99 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 2,349.81 | 3,323.11 | 1,813.21 | 1,145.45 | 1,083.17 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 46.55 | 46.55 | 46.55 | 46.55 | 46.55 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 103.02 | 136.45 | 208.23 | 317.59 | 154.00 | |
| Non-Current Investments Unquoted Book Value | 103.14 | 90.42 | 93.51 | 221.36 | 182.52 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.01 | 0.01 | 81.87 | 378.85 | 0.77 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.70 | 159.72 |
12.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
12.11.2025
10.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL